Literature DB >> 22798503

Diagnostic microRNA markers to screen for sporadic human colon cancer in blood.

Farid E Ahmed1, Nancy C Amed, Paul W Vos, Chris Bonnerup, James N Atkins, Michelle Casey, Gerard J Nuovo, Wade Naziri, John E Wiley, Ron R Allison.   

Abstract

We carried out this study to present proof-of-principal application, showing that by using a global microarray expression analysis, followed by quantitative stem-loop reverse transcriptase in conjunction with TaqMan® polymerase chain reaction (PCR) analysis of micro(mi)RNA genes, on limited number of plasma and tissue samples obtained from 20 individuals (five healthy, five TNM stage 0-1 colon cancer, five stage 2 and five stage 3), we were able to quantitatively monitor miRNA changes at the various TNM stages of colon cancer progression, particularly at the early, pre-malignant adenoma stage (e.g. polyps ≥ 1 cm with high grade dysplasia). The expression of some of the tested miRNAs showed less variability in tissue than in plasma. Nevertheless, our limited preliminary data on the plasma by itself show that plasma is well-suited for screening, and that the quantitative changes in the expression of a few cell-free circulatory mature miRNA molecules in plasma, that are associated with colon cancer progression, would provide for more sensitive and specific markers than those tests currently available on the market. In addition, analysis of miRNA molecules offers a quantitative and cost-effective non-invasive diagnostic approach for screening, than currently employed methods in a prevalent cancer that can be cured if it is detected at the early TNM stages, and that becomes deadly if not diagnosed before metastasis. Thus, a larger prospective and properly randomized clinical study using plasma derived from many control individuals and at various stages of colon cancer (TNM stages 0-IV) from patients, in order to corroborate the initial results, is now urgently needed in order to allow for a statistically valid analysis, standardizing test conditions which will provide a means for determining the true sensitivity and specificity of a miRNA-screening approach. This approach, when combined with bioinformatics analysis to correlate miRNA seed data with mRNA target data, would allow for a mechanistic understanding of how miRNAs regulate mRNA gene expression, and would offer a better comprehensive diagnostic screening test for early-detection of colon cancer non-invasively.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22798503

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  19 in total

Review 1.  The validity of circulating microRNAs in oncology: five years of challenges and contradictions.

Authors:  J Jarry; D Schadendorf; C Greenwood; A Spatz; L C van Kempen
Journal:  Mol Oncol       Date:  2014-03-06       Impact factor: 6.603

Review 2.  Role of Melt Curve Analysis in Interpretation of Nutrigenomics' MicroRNA Expression Data.

Authors:  Farid E Ahmed; Mostafa M Gouda; Laila A Hussein; Nancy C Ahmed; Paul W Vos; Mahmoud A Mohammad
Journal:  Cancer Genomics Proteomics       Date:  2017 Nov-Dec       Impact factor: 4.069

Review 3.  Use of blood-based biomarkers for early diagnosis and surveillance of colorectal cancer.

Authors:  Ganepola Ap Ganepola; Joel Nizin; John R Rutledge; David H Chang
Journal:  World J Gastrointest Oncol       Date:  2014-04-15

4.  MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers.

Authors:  Xu Qian; Jing Yu; Yu Yin; Jun He; Lin Wang; Qi Li; Lou-Qian Zhang; Chong-Yong Li; Zhu-Mei Shi; Qing Xu; Wei Li; Li-Hui Lai; Ling-Zhi Liu; Bing-Hua Jiang
Journal:  Cell Cycle       Date:  2013-04-08       Impact factor: 4.534

Review 5.  Detection of miRNA as non-invasive biomarkers of colorectal cancer.

Authors:  Albert Ren; Yujuan Dong; Ho Tsoi; Jun Yu
Journal:  Int J Mol Sci       Date:  2015-01-27       Impact factor: 5.923

Review 6.  MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer.

Authors:  Lina Cekaite; Peter W Eide; Guro E Lind; Rolf I Skotheim; Ragnhild A Lothe
Journal:  Oncotarget       Date:  2016-02-09

Review 7.  MicroRNAs in colorectal carcinoma--from pathogenesis to therapy.

Authors:  Yudan Chi; Dongming Zhou
Journal:  J Exp Clin Cancer Res       Date:  2016-03-10

8.  Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer.

Authors:  Fung Lin Yong; Chee Wei Law; Chee Woon Wang
Journal:  BMC Cancer       Date:  2013-06-08       Impact factor: 4.430

Review 9.  MicroRNA-92a as a potential biomarker in diagnosis of colorectal cancer: a systematic review and meta-analysis.

Authors:  Xin Yang; Zongyue Zeng; Yixuan Hou; Taixian Yuan; Chao Gao; Wei Jia; Xiaoyan Yi; Manran Liu
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

10.  Rare circulating microRNAs as biomarkers of colorectal neoplasia.

Authors:  Scott V Adams; Polly A Newcomb; Andrea N Burnett-Hartman; Michelle A Wurscher; Margaret Mandelson; Melissa P Upton; Lee-Ching Zhu; John D Potter; Karen W Makar
Journal:  PLoS One       Date:  2014-10-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.